Kelli Gaskins

459 total citations
9 papers, 340 citations indexed

About

Kelli Gaskins is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Kelli Gaskins has authored 9 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Cancer Research and 3 papers in Oncology. Recurrent topics in Kelli Gaskins's work include Cancer, Hypoxia, and Metabolism (3 papers), Glioma Diagnosis and Treatment (2 papers) and Adrenal and Paraganglionic Tumors (2 papers). Kelli Gaskins is often cited by papers focused on Cancer, Hypoxia, and Metabolism (3 papers), Glioma Diagnosis and Treatment (2 papers) and Adrenal and Paraganglionic Tumors (2 papers). Kelli Gaskins collaborates with scholars based in United States, Canada and Pakistan. Kelli Gaskins's co-authors include Electron Kebebew, Myriem Boufraqech, Sudheer Kumar Gara, Naris Nilubol, Dhaval Patel, Maria J. Merino, Carole Sourbier, Lisa Zhang, Jeff Reece and Lisa Zhang and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, JNCI Journal of the National Cancer Institute and Oncogene.

In The Last Decade

Kelli Gaskins

9 papers receiving 339 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kelli Gaskins United States 8 206 106 100 66 56 9 340
Dingyuan Luo China 13 201 1.0× 73 0.7× 140 1.4× 81 1.2× 68 1.2× 22 354
Mary‐Kate Malecek United States 5 203 1.0× 112 1.1× 100 1.0× 35 0.5× 58 1.0× 5 300
Ranran Shi China 11 125 0.6× 71 0.7× 68 0.7× 33 0.5× 43 0.8× 25 302
Kaja Lund Norway 11 231 1.1× 85 0.8× 86 0.9× 32 0.5× 82 1.5× 13 395
Juyong Liang China 10 195 0.9× 110 1.0× 88 0.9× 54 0.8× 36 0.6× 17 371
Xinwei Yun China 11 345 1.7× 99 0.9× 147 1.5× 133 2.0× 56 1.0× 21 509
Sanika Khare United States 6 171 0.8× 58 0.5× 218 2.2× 78 1.2× 112 2.0× 7 368
Lin-ang Wang China 11 189 0.9× 111 1.0× 117 1.2× 25 0.4× 56 1.0× 17 356
Yun Mu China 11 296 1.4× 41 0.4× 166 1.7× 42 0.6× 51 0.9× 16 414
Virginie Quidville France 8 228 1.1× 88 0.8× 129 1.3× 21 0.3× 21 0.4× 10 398

Countries citing papers authored by Kelli Gaskins

Since Specialization
Citations

This map shows the geographic impact of Kelli Gaskins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelli Gaskins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelli Gaskins more than expected).

Fields of papers citing papers by Kelli Gaskins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelli Gaskins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelli Gaskins. The network helps show where Kelli Gaskins may publish in the future.

Co-authorship network of co-authors of Kelli Gaskins

This figure shows the co-authorship network connecting the top 25 collaborators of Kelli Gaskins. A scholar is included among the top collaborators of Kelli Gaskins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelli Gaskins. Kelli Gaskins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Ghosh, Chandrayee, Suresh Kumar, Yevgeniya Kushchayeva, et al.. (2020). A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib). Clinical Cancer Research. 26(8). 2022–2036. 18 indexed citations
2.
Gara, Sudheer Kumar, Dhaval Patel, Kelli Gaskins, et al.. (2020). GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3. Oncotarget. 11(36). 3354–3370. 7 indexed citations
3.
Thakur, Shilpa, Kelli Gaskins, Vasyl Vasko, et al.. (2018). Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In Vitro and In Vivo. Clinical Cancer Research. 24(16). 4030–4043. 108 indexed citations
4.
Nilubol, Naris, Ziqiang Yuan, Giulio F. Paciotti, et al.. (2018). Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors. JNCI Journal of the National Cancer Institute. 110(9). 1019–1029. 19 indexed citations
5.
Nilubol, Naris, Myriem Boufraqech, Lisa Zhang, et al.. (2018). Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response. Oncotarget. 9(68). 33030–33042. 24 indexed citations
6.
Kotian, Shweta, Lisa Zhang, Myriem Boufraqech, et al.. (2017). Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases. Clinical Cancer Research. 23(17). 5044–5054. 63 indexed citations
7.
Liu‐Chittenden, Yi, Kelli Gaskins, Maria J. Merino, et al.. (2017). RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma. Oncogene. 36(25). 3541–3552. 44 indexed citations
8.
Liu‐Chittenden, Yi, Dhaval Patel, Kelli Gaskins, et al.. (2016). Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 101(9). 3345–3352. 17 indexed citations
9.
Zhang, Lisa, Kelli Gaskins, Zhiya Yu, et al.. (2013). An In Vivo Mouse Model of Metastatic Human Thyroid Cancer. Thyroid. 24(4). 695–704. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dingyuan Luo Breakdown of academic impact, for papers by Mary‐Kate Malecek Breakdown of academic impact, for papers by Ranran Shi Breakdown of academic impact, for papers by Kaja Lund Breakdown of academic impact, for papers by Juyong Liang Breakdown of academic impact, for papers by Xinwei Yun Breakdown of academic impact, for papers by Sanika Khare Breakdown of academic impact, for papers by Lin-ang Wang Breakdown of academic impact, for papers by Yun Mu Breakdown of academic impact, for papers by Virginie Quidville
Rankless by CCL
2026